192 related articles for article (PubMed ID: 18201586)
41. Effects of metronidazole on hepatic CYP3A4 activity.
Haas CE; Kaufman DC; DiCenzo RC
Pharmacotherapy; 2001 Oct; 21(10):1192-5. PubMed ID: 11601665
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
43. Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
Wanwimolruk S; Paine MF; Pusek SN; Watkins PB
Br J Clin Pharmacol; 2002 Dec; 54(6):643-51. PubMed ID: 12492613
[TBL] [Abstract][Full Text] [Related]
44. Peritoneal effects of intravenous iron sucrose administration in rats.
Breborowicz A; Polubinska A; Breborowicz M; Simon M; Wanic-Kossowska M; Oreopoulos DG
Transl Res; 2007 Jun; 149(6):304-9. PubMed ID: 17543848
[TBL] [Abstract][Full Text] [Related]
45. Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex.
Breymann C; von Seefried B; Stahel M; Geisser P; Canclini C
J Perinat Med; 2007; 35(2):115-8. PubMed ID: 17302514
[TBL] [Abstract][Full Text] [Related]
46. [Hematological and iron parameters to predict mortality in ESRD].
Cantaro S; Piva E
G Ital Nefrol; 2005; 22 Suppl 31():S135-9. PubMed ID: 15786388
[TBL] [Abstract][Full Text] [Related]
47. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
48. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
49. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
50. Iron storage indices and risk of bacterial infections in hemodialysis patients.
Teehan GS; Ruthazer R; Balakrishnan VS; Snydman D; Jaber BL
Hemodial Int; 2004 Jul; 8(3):226-32. PubMed ID: 19379422
[TBL] [Abstract][Full Text] [Related]
51. Role of oral iron in the management of long-term hemodialysis patients.
Lenga I; Lok C; Marticorena R; Hunter J; Dacouris N; Goldstein M
Clin J Am Soc Nephrol; 2007 Jul; 2(4):688-93. PubMed ID: 17699483
[TBL] [Abstract][Full Text] [Related]
52. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial.
Scharpé J; Peetermans WE; Vanwalleghem J; Maes B; Bammens B; Claes K; Osterhaus AD; Vanrenterghem Y; Evenepoel P
Am J Kidney Dis; 2009 Jul; 54(1):77-85. PubMed ID: 19339089
[TBL] [Abstract][Full Text] [Related]
54. Omega-3 polyunsaturated fatty acids and proxies of cardiovascular disease in hemodialysis: a prospective cohort study.
Vernaglione L; Cristofano C; Chimienti S
J Nephrol; 2008; 21(1):99-105. PubMed ID: 18264942
[TBL] [Abstract][Full Text] [Related]
55. A rapid infusion protocol is safe for total dose iron polymaltose: time for change.
Garg M; Morrison G; Friedman A; Lau A; Lau D; Gibson PR
Intern Med J; 2011 Jul; 41(7):548-54. PubMed ID: 21040319
[TBL] [Abstract][Full Text] [Related]
56. Variability in activity of hepatic CYP3A4 in patients infected with HIV.
Slain D; Pakyz A; Israel DS; Monroe S; Polk RE
Pharmacotherapy; 2000 Aug; 20(8):898-907. PubMed ID: 10939550
[TBL] [Abstract][Full Text] [Related]
57. Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis.
Holman R; Olynyk JK; Kulkarni H; Ferrari P
Nephrology (Carlton); 2017 Feb; 22(2):114-117. PubMed ID: 26824431
[TBL] [Abstract][Full Text] [Related]
58. Intravenous iron sucrose changes the intraperitoneal homeostasis.
Breborowicz A; Połubinska A; Kupczyk M; Wanic-Kossowka M; Oreopoulos DG
Blood Purif; 2009; 28(1):53-8. PubMed ID: 19325240
[TBL] [Abstract][Full Text] [Related]
59. Iron prophylaxis in pregnancy: intravenous route versus oral route.
Bencaiova G; von Mandach U; Zimmermann R
Eur J Obstet Gynecol Reprod Biol; 2009 Jun; 144(2):135-9. PubMed ID: 19406557
[TBL] [Abstract][Full Text] [Related]
60. Studies on the prevalence of reduced salivary flow rate in relation to general health and dental caries, and effect of iron supplementation.
Flink H
Swed Dent J Suppl; 2007; (192):3-50, 2 p preceding table of contents. PubMed ID: 18274060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
